In a recent human [
INTRODUCTION
In agreement with its high in vitro affinity for both D2 and D3 receptors (Freedman et al, 1994; van Vliet et al, 2000) , the agonist positron emission tomography (PET) radiotracer [ 11 C]-( + )-PHNO is thought to label both receptor subtypes in vivo. In both human and baboon, the regional pattern of in vivo [
11 C]-( + )-PHNO binding is unique among D2/D3 radiotracers, with highest binding in the globus pallidus (GP) followed by ventral striatum (VS), caudate (CAU) and putamen (PUT), and substantia nigra (SN) (Ginovart et al, 2007; Narendran et al, 2006; Willeit et al, 2006) . In general agreement with the distribution of D2 and D3 receptors, [
11 C]-( + )-PHNO binding sites in CAU and PUT are thought to represent primarily D2 receptors, whereas those in GP and SN are thought to be primarily of the D3 receptor type (Ginovart et al, 2007; Narendran et al, 2006; Willeit et al, 2006) . The pharmacological dissimilarity between [ 11 C]-( + )-PHNO binding sites in CAU/PUT and GP was first suggested by their anatomical distribution and the slower washout of the radiotracer from GP than from CAU and PUT (Ginovart et al, 2007; Willeit et al, 2006) , but has since been supported by pharmacological evidence showing that [
11 C]-( + )-PHNO binding potential with respect to non-displaceable binding (BP ND ) in the GP can be blocked in a regionally selective manner by the D3-selective drugs BP897 and SB277011 in baboon (Narendran et al, 2006; Rabiner et al, 2009) , and pramipexole (Graff-Guerrero et al, 2009) and ABT-925 (Graff-Guerrero et al, 2008) 3 H]-( + )-PHNO binding in the striatum (STR) while leaving SB277011-sensitive binding in midbrain and cerebellum lobes 9 and 10 largely intact (Rabiner et al, 2009 ).
The observation that [
11 C]-( + )-PHNO labels both D2 and D3 receptors in vivo, coupled with the anatomical separation between regions with primarily D2 (CAU/PUT) or D3 (GP) binding sites, makes [
11 C]-( + )-PHNO a potentially useful radiotracer for measuring occupancy by drugs that bind to either or both receptor types. Antipsychotic drugs, which have similar affinity for D2 and D3 receptors in vitro (Figure 1 ), are expected to occupy comparable proportions of brain D2 and D3 receptor populations. Although it is well established that D2 receptor blockade is required for the therapeutic efficacy of these drugs (Farde et al, 1992; Kapur et al, 2000; Kapur et al, 1999; Nordstrom et al, 1993) , it has been suggested that the D3 receptor may be at least partially responsible for their clinical effect (Joyce and Millan, 2005; Sokoloff et al, 1990) . However, there has traditionally been no way to test the D2 vs D3 binding properties of these drugs in the living brain.
A recent [ 11 C]-( + )-PHNO PET study in schizophrenic patients conducted at our center revealed that chronic treatment with the antipsychotic drugs olanzapine, clozapine, or risperidone, produced high levels of receptor occupancy in D2-rich CAU, PUT, and VS, but no receptor occupancy in D3-rich GP (Graff-Guerrero et al, 2009) . The purpose of this study was to clarify this discrepancy by comparing ex vivo and in vitro D2 and D3 occupancy by olanzapine, clozapine, and risperidone, as well as the typical antipsychotic haloperidol, using [ 
MATERIALS AND METHODS

General
Male Sprague-Dawley rats weighing 250-275 g at the beginning of the study were housed two per cage under a 12 h light 12 h dark photocycle and were allowed unlimited access to food and water. All rats were housed in the animal facility at the Centre for Addiction and Mental Health for 1 week before use in experiments. [ 3 H]-( + )-PHNO (two batches, 50 and 78 Ci/mmol) was purchased from PerkinElmer Life Sciences (Boston, MA). Olanzapine, risperidone, haloperidol, and clozapine were purchased from Bosche Scientific (New Brunswick, NJ), and SB277011 was a gift from Dr Bernard Le Foll at the Centre for Addiction and Mental Health. All animal experiments were conducted with approval of the Animal Ethics Committee at the Centre for Addiction and Mental Health and in accordance with the Canadian Council on Animal Care.
Drug Treatments
Antipsychotic drugs were administered chronically so as to mimic the conditions of the human PET experiment from which this study arose. High-dose chronic olanzapine (7.5 mg/kg/day; 3, 7, 14, or 21 days; n ¼ 4 per group), risperidone (4.2 mg/kg/day; 3 or 21 days; n ¼ 5 per group), haloperidol (0.3 mg/kg/day; 3 or 21 days; n ¼ 5 per group), or chronic vehicle (1% acetic acid in saline; 21 days; n ¼ 18) was administered through implanted osmotic minipumps. Antipsychotic doses were chosen in an attempt to target 90% striatal D2/D3 receptor occupancy based on the results of earlier reports (Kapur et al, 2003; McCormick et al, 2008) . The concentration of antipsychotic drugs required to deliver the above doses was calculated using the predicted rat weight at the midpoint of the treatment period (assuming 7 g daily weight gain) and the known delivery rate of the osmotic minipumps (2.5 and 5 ml/h for 2ML4 and 2ML2 models, respectively). Osmotic minipumps were filled (2 ml total volume) with either vehicle or antipsychotic drug solution and implanted subcutaneously in the animals' upper back under 2.5% isoflurane anesthesia.
The combination of low potency and low solubility of clozapine relative to olanzapine, risperidone, and haloperidol limited the maximum dose that could be delivered through osmotic minipump (Kapur et al, 2003) . Therefore, to achieve striatal D2/D3 receptor occupancy comparable with that of the other antipsychotics, we chose to administer clozapine acutely at a dose of 60 mg/kg, s.c. (n ¼ 12). Acute vehicle-treated rats (2% acetic acid in saline, n ¼ 6) were used as a control group.
To estimate the relative contribution of D2 vs D3 receptors to regional [ D2 and D3 affinities, respectively, are quetiapine 17, 10; remoxipride 8, 7; clozapine 33, 20; olanzapine 19, 12; loxapine 13, 4; ziprazidone 7, 5; risperidone 24, 13; chlorpromazine 19, 10; and haloperidol 39, 22 Twenty mm brain sections were cut at À101C on a Hacker Bright cryostat and thaw mounted onto microscope slides. For each brain, duplicate tissue sections were collected at the following anterior-posterior coordinates (anterior to bregma) (Paxinos and Watson, 1986) and included the following ROIs: (1) 1.6 mm, cerebral cortex (CRT), STR, nucleus accumbens (NACC), islands of Calleja (ICJ); (2) À0.3 mm, STR, ventral pallidum (VP); (3) À5.2 mm, SN; (4) À12.7 mm, CER, cerebellar lobes 9 and 10 (LOB). The brain sections were dried in a dessicator containing Drierite for at least 24 h at 41C and exposed to Fujifilm tritium-sensitive imaging plates (model BAS TR2025) for 4 weeks. Regional tissue radioactivity was determined using a BAS 5000 Fujifilm image plate reader. Ex vivo [ 3 H]-( + )-PHNO binding was quantified using radioactivity in the ROI and CER (as an estimate of non-displaceable binding), as the specific binding ratio, SBR ¼ (ROI-CER)/CER. For each ROI, occupancy was calculated as:
where SBR Drug is the SBR in an individual drug-treated animal and SBR Control is the average SBR in the control vehicle-treated group.
In Vitro [
H]-( + )-PHNO Autoradiography
Five rats were killed by decapitation and their brains removed, frozen on dry ice, and stored at À801C until further use. For each anterior-posterior brain coordinate given above, 16 adjacent 10 mm brain sections were collected. The tissue sections were thaw mounted such that slide #1 contained the most anterior tissue section cut at each brain coordinate, slide #2 contained the next most posterior section from each coordinate, slide #3, the third most posterior, etc. For each brain, all of the 16 resulting sequential slides, therefore, contained all ROIs, but at progressively more posterior positions. In total, 80 slides were produced (5 brains, 16 slides per brain). Each of these 80 slides was then randomly assigned to one of 16 treatment groups. The treatment groups were as follows: control; 47, Slides were incubated for 2 h at room temperature in buffer (50 mM Tris HCl, 1 mM EDTA, 1.5 mM CaCl 2 , 4 mM MgCl 2 , and NaCl either 0.6 nM) containing either 0.6 nM [ 3 H]-( + )-PHNO alone (control) or with one of the above drug concentrations. After incubation, the slides were rinsed in ice-cold buffer (3 Â 5 min), dipped for 10 s in ice-cold deionized water, and dried under a stream of room temperature air. The slides were left to dry further overnight and exposed to tritium-sensitive image plates for 3 weeks in the presence of calibrated methacrylate radioactivity standards. The image plates were scanned and regional [ H]-( + )-PHNO binding (SBR for ex vivo and SB for in vitro experiments) between drugtreated and control groups was performed by ANOVA followed by Dunnett's multiple comparison test. Occupancy was considered significant when the SBR or SB in the drugtreated group was significantly different from that in the respective control group. Evaluation of occupancy differences between ex vivo and in vitro conditions was performed by ANOVA followed by Bonferroni's multiple comparison test.
RESULTS
Ex Vivo [ 3 H]-( + )-PHNO Autoradiography
Typical ex vivo and in vitro [ Figure 3 (top panel). The highest SBR was seen in the ICJ (8.0±2.0) followed by STR (4.4±1.0), NACC (2.5±0.7), LOB (2.0 ± 0.5), VP (1.6 ± 0.4), and SN (0.5 ± 0.2). The lowest SBR was seen in CRT (0.1 ± 0.1).
For rats treated with chronic risperidone or haloperidol, regional occupancy and plasma drug concentrations (Table 1) were similar for all treatment durations (p40.05). We, therefore, chose to pool the data to produce a single group for each drug to increase statistical power. During chronic olanzapine treatment, plasma olanzapine concentration decreased over time as has been reported earlier (van der Zwaal et al, 2008) (Table 1) , resulting in slightly reduced STR occupancy in the 14-and 21-day treatment groups (po0.01, 74 ± 7 and 71 ± 8%, respectively, vs 88±7% in the 3-day treatment group). No other differences in regional occupancy were seen between olanzapine-treated groups. Consequently, we chose to also pool the chronic olanzapine data, with the understanding that this pooled group underestimates the occupancy in STR by B7% relative to the 3-day treatment group. Figure 4 shows ex vivo occupancy (left panels) in comparison with that measured in vitro (right panels). Treatment with chronic 7.5 mg/kg/day olanzapine plus 10 mg/kg acute SB277011 resulted in extensive receptor occupancy across all brain regions: STR, 90±3%; NACC, 80±5%; 83±5%; SN, 89±10%; ICJ, 68±14%; LOB, 82 ± 6%. Average ex vivo occupancy ± SD can also be found in Supplementary Figure 2 (right panels) and regional in vitro SB is shown in Figure 3 (bottom panel). [ 3 H]-( + )-PHNO SB was highest in STR (1164 ± 129 fmol/g), followed by NACC (836±77 fmol/g), VP (118±29 fmol/g), SN (85±20 fmol/g), LOB (65 ± 7 fmol/g), and CRT (23 ± 7 fmol/g). Total binding in CER (used as an estimate of non-displaceable binding) was 29±7 fmol/g. Figure 4 (right panels) shows the regional occupancy produced by the highest concentration SB277011 and each of the antipsychotic drugs in comparison with the occupancy observed ex vivo. The occupancy produced by the remaining two antipsychotic concentrations can be found in Supplementary Table 3 . suggests that these differences are due to reduced binding in D3-rich areas. Although the SBR (ex vivo) and SB (in vitro) cannot be directly compared, quantitative differences between ex vivo and in vitro [ 3 H]-( + )-PHNO binding can be illustrated by normalization of regional binding to that in STR, which, as discussed below, is exclusively due to D2 binding and should thus be unaffected by changes in D3 binding. Relative to STR, ex vivo binding in LOB (45% of SBR in STR), VP (36% of STR), and SN (11% of STR) is significantly greater than seen in vitro (6, 10, and 7% of STR, respectively; t test, po0.001 for LOB and VP, po0.05 for SN), whereas no difference is seen in NACC (p40.05). The decrease in LOB, VP, and SN binding relative to STR is also reflected in the distinctive change in regional rank order of [ 3 H]-( + )-PHNO binding between the ex vivo (STR4NACC4LOB4VP4SN4CRT) and in vitro (STR4NACC4VPBSNBLOB4CRT) conditions, which would not be expected if the ex vivo vs in vitro differences in baseline binding were due to altered D2 receptor binding. Unfortunately, because ROIs could not be reliably drawn around ICJ in the in vitro condition, a direct comparison between ex vivo and in vitro binding in this region was not possible. However, the fact that the ICJ were more easily distinguishable ex vivo suggests an increased ex vivo vs in vitro signal in this region similar to that seen in LOB and VP.
DISCUSSION
Although the anatomical pattern of D2-like receptor binding is well established (Bancroft et al, 1998; Levant, 1998) , the ratio of D2 to D3 receptor binding sites within individual brain region is not precisely known. Pretreatment with the B100-fold D3-selective drug SB277011 (Newman et al, 2005) ]-( + )-PHNO binding in ICJ is larger than indicated here, as the ROIs drawn around these small structures probably included some spillover from the D2-rich olfactory tubercle. The anatomical separation and relatively large size of the other regions are more amenable to accurate ROI delineation, and our reported D3 contribution in these regions is more certain.
In vitro, the same regional trend in SB277011 occupancy was seen (Figure 4) (Schotte et al, 1996a) . However, endogenous dopamine does not seem to be relevant to the current data, as the extensive dilution of dopamine into the in vitro assay volume (12 ml volume over 60 min) would be expected to increase, rather than decrease, [ 3 H]-( + )-PHNO binding in the VP (relative to the ex vivo condition), and to have little or no effect on binding in LOB, which lacks dopaminergic innervation (Beckstead et al, 1979; Swanson, 1982) . It is possible that the D3 receptor high-affinity state is selectively disrupted in vitro, resulting in lower D3 receptor [ 3 H]-( + )-PHNO binding. However, this explanation also seems unlikely given that the D3 receptor-G protein complex responsible for high-affinity agonist binding is thought to be more stable than that of the D2 receptor (Seabrook et al, 1992; Sokoloff et al, 1990) . Many other potential differences exist between our in vitro and ex vivo conditions (eg disruption of ionic gradients, membrane voltage and protein kinase/phosphatase cycles) and further investigation would be necessary to unravel their relevance to the current data. Fortunately, both ex vivo and in vitro, the pure D3 and D2 [ 3 H]-( + )-PHNO binding signal in LOB and STR, respectively, makes these regions ideally suited for the examination of drug occupancy at these receptor types. However, in other regions, the D3 vs D2 contribution to [ 3 H]-( + )-PHNO binding depends, at least under our experimental conditions, on whether the measurements are made in vitro or ex vivo and drug occupancy in these regions must be interpreted accordingly. The antipsychotic drugs olanzapine (7.5 mg/kg/day), clozapine (60 mg/kg), risperidone (4.2 mg/kg/day), and haloperidol (0.3 mg/kg/day) occupied a large proportion (B80%) of ex vivo [ 3 H]-( + )-PHNO binding sites in STR, in agreement with their well-known D2 antagonism. However, despite their reportedly similar affinity for D2 and D3 receptors, olanzapine, risperidone, and haloperidol did not measurably occupy D3 receptors in LOB. As well, clozapine occupancy in LOB was lowest among the ROIs examined. Ex vivo antipsychotic occupancy across all regions followed a trend that was the inverse of that seen for the D3-selective drug SB277011 (Figure 3) . Using in vitro [ 3 H]-( + )-PHNO autoradiography, we confirmed that all of these drugs produce similar occupancy in STR, NACC, SN, VP, and LOB. These data provide strong pharmacological evidence that these drugs are in fact D2-selective ex vivoFa surprising finding given their in vitro pharmacological profile. Similar results have been reported by Schotte et al (1996a) . Their autoradiographic experiments involved in vivo antipsychotic treatment followed by measurement of receptor occupancy using in vitro [
3 H]-7-OH-DPAT (D3 receptors in ICJ) or [ 125 I]-iodosulpiride (nominally D2 receptors in NACC). They report that when administered in vivo, clozapine, olanzapine, risperidone, and haloperidol had ratios of D2 to D3 potency 2-10 times higher than when determined using in vitro competitive binding experiments, and argued that this effect was due to the in vivo inhibitory influence of endogenous dopamine on antipsychotic D3 receptor binding. However, this explanation cannot account for our observation that the antipsychotic drugs have lower potency for D3 receptors in LOB, which lacks dopaminergic innervation (Beckstead et al, 1979; Swanson, 1982) , than for D2 receptors in STR, nor can it explain the inverse regional trend between antipsychotic occupancy and SB277011 occupancy. Our data are explained more completely by a model in which the in vivo D2/D3-affinity ratio for antipsychotics is greater than predicted by in vitro measurements.
Clinically, most antipsychotic drugs produce therapeutic effects at doses producing 65-80% D2 receptor occupancy (Farde et al, 1992; Kapur et al, 2000; Kapur et al, 1999; Nordstrom et al, 1993) . The levels of D2 occupancy in this study are on the high end of this occupancy range (B80%), suggesting that at clinically relevant doses, the therapeutic effects of olanzapine, risperidone, and haloperidol are not attributable to D3 receptor blockade. Clozapine was the only antipsychotic to produce significant occupancy in LOB, suggesting that its selectivity for D2 over D3 receptors in living brain is less than that of the other antipsychotics. This does not seem to be a consequence of the fact that clozapine was administered acutely rather than chronically, as the duration of treatment had little effect on regional occupancy produced by the other antipsychotics. Nevertheless, the clinical importance of the D3 receptor to clozapine's clinical effect is likely small, as the D2 occupancy of therapeutic clozapine (20-60%) (Kapur et al, 1999; Nordstrom et al, 1995) is typically less than for the other antipsychotic, indicating that clozapine's D3 receptor occupancy in the clinical setting is likely also much lower than the 35% occupancy seen here. Indeed the recent PET study by our group in schizophrenic patients found that chronic clozapine treatment, while producing B50% occupancy in STR, did not reduce [
11 C]-( + )-PHNO binding in the GP (Graff-Guerrero et al, 2009) .
The current data point to the importance of in vivo or ex vivo experiments in elucidating the mechanism of action of therapeutic agents within the brain. As we show here, in vitro pharmacological measurement, although invaluable in drug and radiotracer development, can sometimes lead to erroneous assumptions regarding in vivo drug action. Ex vivo [ 3 H]-( + )-PHNO autoradiography is a powerful technique for determining, with high anatomical resolution, the interaction of drugs with both D2 (STR) and D3 (LOB) receptors in the living brain. In particular, ex vivo autoradiography has two major strengths for preclinical drug evaluation in rat or other small research animals. First, unlike small animal PET experiments, ex vivo autoradiography does not require the use of anesthesia, which can confound interpretation of radiotracer binding results (Tsukada et al, 2000; Tsukada et al, 2008) . Second, the spatial resolution of autoradiography is very high in comparison with either ex vivo dissection experiments or in vivo small animal PET experiments. The major limitation of this technique, however, is that, barring the use of prohibitively large numbers of animals, it is not easily amenable to generation of multiple time point data that can be analyzed using quantitative radiotracer pharmacokinetic modeling techniques. For dopamine receptor radiotracers, pharmacokinetic modeling is typically used to derive BP ND . This equilibrium parameter, which expresses the ratio of specific to non-displaceable radiotracer distribution volumes, is commonly used as an index of receptor availability. The ratio methods, such as that used to generate our ex vivo SBR (equivalent to STR/CERF1), are common non-kinetic methods that use a non-equilibrium ratio of ROI to reference tissue radiotracer concentrations to estimate BP ND . The two most common ratio methods are the transient equilibrium and late time point methods. The transient equilibrium method uses the ratio of ROI to reference tissue radiotracer concentrations at a time point corresponding to peak SB (so-called transient equilibrium) (Carson et al, 1993; Ginovart et al, 2001; Ito et al, 1998) . At this particular time point, the SBR is mathematically equivalent to BP ND . The late time point method, which is used in this study, instead uses the ratio of ROI to reference tissue concentrations at some time after transient equilibrium has been reached (B30 min for [ 11 C]-( + )-PHNO in rat) Ginovart et al, 2001; Ito et al, 1998; Lammertsma et al, 1996) . Relative to the transient equilibrium method (Carson et al, 1993; Ginovart et al, 2001; Ito et al, 1998) , the late time point method can result in overestimate of BP ND (Ito et al, 1998; Lammertsma et al, 1996) , the magnitude of this bias related to the regional kinetics of the radiotracer. This may have bearing on interpretation of the current results. In human, the kinetics of [ 11 C]-( + )-PHNO binding in the D2-rich dorsal STR are very different from those in the D3-rich GP (Ginovart et al, 2007) . If such regional kinetic differences were to exist in rat, they could result in greater overestimate of SBR in D3-rich vs D2-rich regions, possibly helping to explain some of the quantitative difference between our ex vivo and in vitro results. Inspection of published human (Ginovart et al, 2007) , however, suggests exactly the opposite; that an SBR calculated using a late time point (60 min.) overestimates BP ND to a larger extent in D2-rich CAU-PUT than in the D3-rich GP. However, in the absence of detailed regional [ 3 H]-( + )-PHNO kinetic data in rat, it is impossible to make firm statements regarding the influence of regional kinetics on the current data. In general, ratio methods can be expected to result in reliable quantification of inter-group differences in radiotracer binding and receptor occupancy provided that no large differences in radiotracer delivery exist between groups (Fujita, 2001; Ginovart et al, 2001; Ito et al, 1998) . Such delivery differences, typically attributable to intergroup differences in cerebral blood flow, can alter ROI-toreference tissue ratios and thus confound interpretation of group differences in radiotracer binding. To the authors' knowledge, antipsychotic drugs are not known to cause changes in cerebral blood flow large enough to explain our results (Yildiz et al, 2000) . Further, supporting the validity of the ratio method used here is the general agreement between the current findings and the results of our earlier (Ginovart et al, 2007) . Nevertheless, given the methodological limitations of our late time point ratio method (eg sensitivity to blood flow changes and regional kinetic differences), the current findings should be confirmed using multiple time point ex vivo experiments or in vivo using small animal PET.
Another methodological limitation worth considering is the fact that receptor binding in our ex vivo experiments occurred at body temperature of B371C, whereas our in vitro binding studies were conducted at room temperature (B201C). The ex vivo vs in vitro differences in antipsychotic occupancy observed here could theoretically be explained by a selective decrease in antipsychotic affinity for the D3 receptor with increasing temperature (ie greater D2 receptor selectivity in our ex vivo experiments). However, close examination of the in vitro literature provides no support for this hypothesis, as all of the antipsychotics examined here also have similar in vitro D2 and D3 affinity at 371C, with none displaying 44.4-fold selectivity for either receptor subtype (Kongsamut et al, 1996; Leopoldo et al, 2002; Schotte et al, 1996b; Tang et al, 1994) .
In addressing the limitations of our study, it is worthwhile also to consider whether our relatively large injected [ 3 H]-( + )-PHNO dose (B5.7 nmol/kg vs 0.3-3 nmol/kg in our earlier studies) falls within the tracer dose range (commonly defined by receptor occupancy not exceeding 5%). Within this dose range, our ex vivo SBR (a saturable signal) should be relatively insensitive to changes in injected mass, as opposed, for example, to a dose range surrounding the EC 50 in which small changes in injected dose would result in large reductions in the SBR. Our striatal SBR of 4.5 is identical to that in our earlier reports, which used 2-to 10-fold lower injected mass (McCormick et al, 2009; McCormick et al, 2008; and unpublished data) , suggesting that the tracer dose range for the D2 receptor extends at least as high as the current injected dose of 5.7 nmol/kg. Second, exceeding the tracer dose range would result in an underestimate of antipsychotic D2 receptor occupancy. We find, however, that our current striatal clozapine D2 occupancy (80 ± 7%) is very similar to that of our earlier report (80 ± 8%) in which a twofold lower injected [ compensation from Abbott Laboratories, grant support from Janssen, and speaker compensation from Eli Lilly. Shitij Kapur has received grant support from AstraZeneca, Bristol-Myers Squibb, and Glaxo Smith Kline, and has acted as consultant/scientific advisor or received speaker compensation from AstraZeneca, Bioline, Bristol-Meyers Squibb, Eli Lilly, Janssen, Lundbeck, Otsuka, Organon, Pfizer, Servier, and Solvay Wyeth.
